Special Reports, Gastrointestinal Cancers (Issue 4), Volume 4, Issue 1
Chiara Cremolini, MD, discusses the phase III TRIBE trial, which compared FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as for patients with metastatic colorectal cancer.
Chiara Cremolini, MD, a medical oncologist at the Tuscan Tumor Institute in Pisa, Italy, discusses updated results from the phase III TRIBE trial, which compared FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as a first-line treatment for patients with metastatic colorectal cancer (mCRC).
Clinical Pearls:
The study was used to compare progression-free and overall survival rates for patients with mCRC using FOLFOXIRI plus bevacizumab and FOLFIRI with bevacizumab.
Patients in the FOLFOXIRI arm achieved an overall survival rate of 29.8 months, versus 25.8 months for patients in the FOLFIRI arm.
1 out of 4 ​patients who were given FOLFOXIRI plus bevacizumab had a survival rate of 5 years, as compared to 1 out of 8 patients who were treated with FOLFIRI plus bevacizumab.
